Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers

Archives of Cardiovascular Diseases

Volumn 106, Issue 12, 2013, Pages 661-671

  Funck Brentano, Christian ^a,b,c   Szymezak, Jean ^d   Steichen, Olivier ^a   Ducint, Dominique ^e   Molimard, Mathieu ^e,f   Remones, Véronique ^d   Azizi, Michel ^a,d,g   Gaussem, Pascale ^a,d,g  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Clopidogrel; CYP2C19 protein; Drug interactions; Proton pump inhibitors; Vasodilator stimulated phosphoprotein

Indexed keywords

CLOPIDOGREL; OMEPRAZOLE; PLACEBO; RABEPRAZOLE;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DETERMINATION; DRUG EFFICACY; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE FUNCTION ANALYZER;

ADENOSINE DIPHOSPHATE; ADP; CLOPIDOGREL; CYP; CYP2C19; CYP2C19 PROTEIN; CYTOCHROME P-450; DRUG INTERACTIONS; EM; EXTENSIVE METABOLIZER; INHIBITEURS DE POMPES À PROTONS; INHIBITION OF PLATELET AGGREGATION; INTERACTIONS MÉDICAMENTEUSES; IPA; MAXIMAL PLATELET AGGREGATION; MEAN FLUORESCENCE INTENSITY; MFI; MPA; PGE1; PLATELET REACTIVITY INDEX; PPI; PRI; PROSTAGLANDIN E1; PROTÉINE VASP; PROTON-PUMP INHIBITORS; VASODILATOR-STIMULATED PHOSPHOPROTEIN; VASP;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BLOOD PLATELETS; CELL ADHESION MOLECULES; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICROFILAMENT PROTEINS; OMEPRAZOLE; PARIS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RABEPRAZOLE; TICLOPIDINE;

EID: 84889887658     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2013.09.002     Document Type: Article

References (49)

1. S.C. Smith Jr., E.J. Benjamin, and R.O. Bonow AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 Update: a guideline from the American Heart Association and American College of Cardiology Foundation Circulation 124 2011 2458 2473
2. C.W. Hamm, J.P. Bassand, and S. Agewall ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
3. J.S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
4. M. Kazui, Y. Nishiya, and T. Ishizuka Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
5. T.K. Ma, Y.Y. Lam, and V.P. Tan Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel Pharmacol Ther 125 2010 249 259
6. J.T. Delaney, A.H. Ramirez, and E. Bowton Predicting clopidogrel response using DNA samples linked to an electronic health record Clin Pharmacol Ther 91 2012 257 263
7. M.V. Holmes, P. Perel, and T. Shah CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis JAMA 306 2011 2704 2714
8. T. Bauer, H.J. Bouman, and J.W. van Werkum Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis BMJ 343 2011 d4588
9. L.C. Saiz, J. Alvarez, and H. Martinez Drug regulatory agencies' role in the interaction between clopidogrel and proton pump inhibitors Am J Gastroenterol 106 2011 1369 1370
10. M. Schmidt, M.B. Johansen, and D.J. Robertson Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation Aliment Pharmacol Ther 35 2012 165 174
11. M. Zabalza, I. Subirana, and J. Sala Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel Heart 98 2012 100 108
12. U.S. Tantry, D.J. Kereiakes, and P.A. Gurbel Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 4 2011 365 380
13. K. Hagymasi, K. Mullner, and L. Herszenyi Update on the pharmacogenomics of proton pump inhibitors Pharmacogenomics 12 2011 873 888
14. X.Q. Li, T.B. Andersson, and M. Ahlstrom Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities Drug Metab Dispos 32 2004 821 827
15. T. Furuta, N. Shirai, and M. Sugimoto Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies Drug Metab Pharmacokinet 20 2005 153 167
16. T. Sakai, N. Aoyama, and T. Kita CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects Pharm Res 18 2001 721 727
17. U. Klotz, M. Schwab, and G. Treiber CYP2C19 polymorphism and proton pump inhibitors Basic Clin Pharmacol Toxicol 95 2004 2 8
18. H. Fernando, N. Bassler, and J. Habersberger Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel J Thromb Haemost 9 2011 1582 1589
19. D.J. Angiolillo, C.M. Gibson, and S. Cheng Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies Clin Pharmacol Ther 89 2011 65 74
20. F. Zhao, J. Wang, and Y. Yang Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis Helicobacter 13 2008 532 541
21. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study J Am Coll Cardiol 51 2008 256 260
22. J.S. Hulot, J.P. Collet, and J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
23. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
24. I.J. Douglas, S.J. Evans, and A.D. Hingorani Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs BMJ 345 2012 e4388
25. K.J. Harjai, C. Shenoy, and P. Orshaw Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators Circ Cardiovasc Interv 4 2011 162 170
26. F.Y. Hsiao, C.D. Mullins, and Y.W. Wen Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome Pharmacoepidemiol Drug Saf 20 2011 1043 1049
27. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents Circulation 122 2010 2619 2633
28. D.L. Bhatt, B.L. Cryer, and C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
29. D. Sibbing, T. Morath, and J. Stegherr Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 2009 714 719
30. A.L. Frelinger 3rd, R.D. Lee, and D.J. Mulford A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers J Am Coll Cardiol 59 2012 1304 1311
31. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
32. Y. Liang, M. Johnston, and J. Hirsh Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin J Thromb Thrombolysis 34 2012 429 436
33. H.J. Bouman, E. Parlak, and J.W. van Werkum Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel J Thromb Haemost 8 2010 482 488
34. M. Christensen, K. Andersson, and P. Dalen The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes Clin Pharmacol Ther 73 2003 517 528
35. M. Ramsjö, E. Aklillu, and L. Bohman CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking Eur J Clin Pharmacol 66 2010 871 877
36. M. Chang, M.L. Dahl, and G. Tybring Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype Pharmacogenetics 5 1995 358 363
37. J.S. Hulot, G. Wuerzner, and C. Bachelot-Loza Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects J Thromb Haemost 8 2010 610 613
38. Y.H. Jeong, K.P. Bliden, and U.S. Tantry High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost 10 2012 487 489
39. N.J. Breet, J.W. van Werkum, and H.J. Bouman High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention Heart 97 2011 983 990
40. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
41. S. Yasuda, Y. Horai, and Y. Tomono Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status Clin Pharmacol Ther 58 1995 143 154
42. N.B. Norgard, K.D. Mathews, and G.C. Wall Drug-drug interaction between clopidogrel and the proton pump inhibitors Ann Pharmacother 43 2009 1266 1274
43. R. Ogawa, and H. Echizen Drug-drug interaction profiles of proton pump inhibitors Clin Pharmacokinet 49 2010 509 533
44. M. Wurtz, E.L. Grove, and S.D. Kristensen The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease Heart 96 2010 368 371
45. O.H. Ali, and C.E. Uzoigwe Proton pump inhibitor and clopidogrel interaction: have we forgotten aspirin? Br J Haematol 155 2011 407 408
46. M. Charlot, O. Ahlehoff, and M.L. Norgaard Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study Ann Intern Med 153 2010 378 386
47. M. Charlot, E.L. Grove, and P.R. Hansen Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study BMJ 342 2011 d2690
48. S. Siriswangvat, N. Sansanayudh, and S. Nathisuwan Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel Circ J 74 2010 2187 2192
49. J. Wu, L.T. Jia, and L.M. Shao Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers Eur J Clin Pharmacol 69 2013 179 187